These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 35943868)

  • 1. Pharmacokinetics of Emtricitabine/Tenofovir Disoproxil Fumarate Among Transgender Adolescents and Young Adults Without HIV Receiving Gender Affirming Hormones.
    Yager J; Brooks KM; Brothers J; Mulligan K; Landovitz R; Reirden D; Glenny C; Malhotra M; Anderson PL; Hosek S
    AIDS Res Hum Retroviruses; 2022 Nov; 38(11):840-846. PubMed ID: 35943868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gender-Affirming Hormone Pharmacokinetics Among Adolescent and Young Adult Transgender Persons Receiving Daily Emtricitabine/Tenofovir Disoproxil Fumarate.
    Yager J; Brooks KM; Brothers J; Mulligan K; Landovitz RJ; Reirden D; Malhotra M; Glenny C; Harding P; Powell T; Anderson PL; Hosek S
    AIDS Res Hum Retroviruses; 2022 Dec; 38(12):939-943. PubMed ID: 35815468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transgender women on oral HIV pre-exposure prophylaxis have significantly lower tenofovir and emtricitabine concentrations when also taking oestrogen when compared to cisgender men.
    Shieh E; Marzinke MA; Fuchs EJ; Hamlin A; Bakshi R; Aung W; Breakey J; Poteat T; Brown T; Bumpus NN; Hendrix CW
    J Int AIDS Soc; 2019 Nov; 22(11):e25405. PubMed ID: 31692269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gender Affirming Hormones Do Not Affect the Exposure and Efficacy of F/TDF or F/TAF for HIV Preexposure Prophylaxis: A Subgroup Analysis from the DISCOVER Trial.
    Cespedes MS; Das M; Yager J; Prins M; Krznaric I; de Jong J; Xiao D; Shao Y; Wong P; Kintu A; Carter C; Hoornenborg E; Ruane P; Phoenix J; Younis I; Halperin J
    Transgend Health; 2024 Feb; 9(1):46-52. PubMed ID: 38312459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacology and drug interactions with HIV PrEP in transgender persons receiving gender affirming hormone therapy.
    Yager JL; Anderson PL
    Expert Opin Drug Metab Toxicol; 2020 Jun; 16(6):463-474. PubMed ID: 32250177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing.
    Castillo-Mancilla J; Seifert S; Campbell K; Coleman S; McAllister K; Zheng JH; Gardner EM; Liu A; Glidden DV; Grant R; Hosek S; Wilson CM; Bushman LR; MaWhinney S; Anderson PL
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6692-6697. PubMed ID: 27572401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adherence and HIV Protection Thresholds for Emtricitabine and Tenofovir Disoproxil Fumarate Preexposure Prophylaxis among Cisgender Women: A Systematic Review.
    Wu L; Niu X; Brunelli MK; Mugwanya KK
    Curr HIV/AIDS Rep; 2024 Oct; 21(5):264-281. PubMed ID: 39120667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No observed bidirectional effect between tenofovir diphosphate concentrations and gender-affirming hormone concentrations among transgender persons switching from tenofovir disoproxil fumarate/emtricitabine to tenofovir alafenamide/emtricitabine for HIV pre-exposure prophylaxis.
    Patel N; Morris S; Burke L; Chow K; Pacheco D; Anderson P; Stancyzk F; Blumenthal J
    Br J Clin Pharmacol; 2024 Oct; 90(10):2360-2365. PubMed ID: 38646796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sex Hormone Therapy and Tenofovir Diphosphate Concentration in Dried Blood Spots: Primary Results of the Interactions Between Antiretrovirals And Transgender Hormones Study.
    Grant RM; Pellegrini M; Defechereux PA; Anderson PL; Yu M; Glidden DV; O'Neal J; Yager J; Bhasin S; Sevelius J; Deutsch MB
    Clin Infect Dis; 2021 Oct; 73(7):e2117-e2123. PubMed ID: 32766890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS Study.
    Yager J; Castillo-Mancilla J; Ibrahim ME; Brooks KM; McHugh C; Morrow M; McCallister S; Bushman LR; MaWhinney S; Kiser JJ; Anderson PL
    J Acquir Immune Defic Syndr; 2020 Jul; 84(3):323-330. PubMed ID: 32539288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates.
    Chen X; Seifert SM; Castillo-Mancilla JR; Bushman LR; Zheng JH; Kiser JJ; MaWhinney S; Anderson PL
    PLoS One; 2016; 11(11):e0165505. PubMed ID: 27832147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose finding study for on-demand HIV pre-exposure prophylaxis for insertive sex in sub-Saharan Africa: results from the CHAPS open label randomised controlled trial.
    Herrera C; Serwanga J; Else L; Limakatso L; Opoka D; Ssemata AS; Pillay AD; Namubiru P; Seiphetlo TB; Odoch G; Mugaba S; Seatlholo P; Alieu A; Penchala SD; Muhumuza R; Alinde B; Petkov S; O'Hagan K; Callebaut C; Seeley J; Weiss H; Khoo S; Chiodi F; Gray CM; Kaleebu P; Webb EL; Martinson N; Fox J;
    EBioMedicine; 2023 Jul; 93():104648. PubMed ID: 37327677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of pharmacokinetics of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil (TDF) in pregnant and postpartum women in South Africa: PrEP-PP PK study.
    Joseph Davey D; Dadan S; Bheemraj K; Waitt C; Khoo S; Myer L; Wiesner L; Else L; Thompson B; Castel S; Wara N; Anderson PL; Orrell C
    Antiviral Res; 2024 Nov; 231():106014. PubMed ID: 39332538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tenofovir-diphosphate in peripheral blood mononuclear cells during low, medium and high adherence to emtricitabine/ tenofovir alafenamide vs. emtricitabine/ tenofovir disoproxil fumarate.
    Yager JL; Brooks KM; Castillo-Mancilla JR; Nemkov C; Morrow M; Peterson S; Ibrahim M; Bushman L; Kiser JJ; MaWhinney S; Anderson PL
    AIDS; 2021 Dec; 35(15):2481-2487. PubMed ID: 34482350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intracellular Tenofovir and Emtricitabine Anabolites in Genital, Rectal, and Blood Compartments from First Dose to Steady State.
    Seifert SM; Chen X; Meditz AL; Castillo-Mancilla JR; Gardner EM; Predhomme JA; Clayton C; Austin G; Palmer BE; Zheng JH; Klein B; Kerr BJ; Guida LA; Rower C; Rower JE; Kiser JJ; Bushman LR; MaWhinney S; Anderson PL
    AIDS Res Hum Retroviruses; 2016; 32(10-11):981-991. PubMed ID: 27526873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma and intracellular pharmacokinetics of tenofovir disoproxil fumarate and emtricitabine in transgender women receiving feminizing hormone therapy.
    Cirrincione LR; Podany AT; Havens JP; Bares SH; Dyavar SR; Gwon Y; Johnson TM; Amoura NJ; Fletcher CV; Scarsi KK
    J Antimicrob Chemother; 2020 May; 75(5):1242-1249. PubMed ID: 32065631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure.
    Castillo-Mancilla JR; Zheng JH; Rower JE; Meditz A; Gardner EM; Predhomme J; Fernandez C; Langness J; Kiser JJ; Bushman LR; Anderson PL
    AIDS Res Hum Retroviruses; 2013 Feb; 29(2):384-90. PubMed ID: 22935078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066).
    Hendrix CW; Andrade A; Bumpus NN; Kashuba AD; Marzinke MA; Moore A; Anderson PL; Bushman LR; Fuchs EJ; Wiggins I; Radebaugh C; Prince HA; Bakshi RP; Wang R; Richardson P; Shieh E; McKinstry L; Li X; Donnell D; Elharrar V; Mayer KH; Patterson KB
    AIDS Res Hum Retroviruses; 2016 Jan; 32(1):32-43. PubMed ID: 26414912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics of tenofovir, emtricitabine and intracellular metabolites in transgender women.
    Tanaudommongkon A; Chaturvedula A; Hendrix CW; Fuchs EJ; Shieh E; Bakshi RP; Marzinke MA
    Br J Clin Pharmacol; 2022 Aug; 88(8):3674-3682. PubMed ID: 35285974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy.
    Anderson PL; Liu AY; Castillo-Mancilla JR; Gardner EM; Seifert SM; McHugh C; Wagner T; Campbell K; Morrow M; Ibrahim M; Buchbinder S; Bushman LR; Kiser JJ; MaWhinney S
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.